Michael J. Morris, MD, of Memorial Sloan Kettering Cancer Center, discusses phase III data from the CONDOR trial, which showed that PSMA-targeted PET scans detected and localized occult disease in most men with biochemically recurrent prostate cancer presenting with negative or equivocal conventional imaging findings (Abstract 5501).
Christopher Sweeney, MBBS, of Dana-Farber Cancer Institute, talks with Thomas Powles, MD, PhD, of Queen Mary University of London, about the first study to d...
Seema A. Khan, MD, MPH, of the Lynn Sage Comprehensive Breast Center, discusses phase III trial results showing that in newly diagnosed metastatic stage IV breast cancer, loc...
Howard A. Burris III, MD, FACP, FASCO, President of ASCO, talks about what to expect from this year’s ASCO20 Virtual Scientific Program and its many offerings.
David C. Fajgenbaum, MD, MBA, of the University of Pennsylvania, who trained as an oncologist, summarizes his opening lecture, a dramatic story of his battle against Castlema...
Howard A. Burris III, MD, FACP, FASCO, talks about some of the reports of research developments he is looking forward to and how future conferences could incorporate virtual ...